Table 2.

Twelve areas of controversy as discussed at the panel discussion in St. Gallen, Saturday March 16, 2013

Surgery of the primary Surgery of the axilla Radiation: partial breast, post-mastectomy, nodal areas, advanced technologies Pathology: Ki-67, ER, HER2, grade, other markers Multi-gene signatures: 21 gene RS, PAM-50, 70 gene signature, EPClin, other Stroma: extracellular matrix and prognosis Endocrine therapies: ovarian suppression, tamoxifen, aromatase inhibitors Chemotherapies: luminal A, duration, regimen Anti-HER2 therapies: combination, duration Neo-adjuvant systemic therapy Bisphosphonates: anti-tumor effects Follow-up after early breast cancer